We ask the UK Government to reschedule psilocybin, moving it from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations 2001, to allow it to be used in clinical trials.

We ask the UK Government to reschedule psilocybin from Schedule 1 to Schedule 2 to allow medical research. Some studies show psilocybin can reduce depression, anxiety, and PTSD symptoms under clinical supervision. Rescheduling could enable safe, regulated research and potential therapeutic use.